{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-228534","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2022-08-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.141325+00:00","generated_at":"2026-06-23T21:38:11.416001+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Alnylam elects Dr. Elliott Sigal to Board, expanding size to 11 members","bullets":["Dr. Sigal elected as Class I director effective Aug 22, 2022; term expires at 2023 annual meeting.","Annual cash fee of $55,000 for non-employee director service.","Initial stock option for 4,456 shares at $217.91/share, $600K grant-date value, vesting over 3 years.","Eligible for annual option award of $400K grant-date value beginning in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-228534","json":"https://secwatch.observer/filing/0001193125-22-228534.json","markdown":"https://secwatch.observer/filing/0001193125-22-228534.md","text":"https://secwatch.observer/filing/0001193125-22-228534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522228534/0001193125-22-228534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522228534/d335044d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:38:11.416001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b2c4379a9","claim":"Dr. Elliott Sigal was elected as Director at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"Effective as of August 22, 2022, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Dr. Elliott Sigal to fill the newly created vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312522228534/0001193125-22-228534-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}